Overview

Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC

Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The study is a prospective, multi-center, open-label, randomized, and controlled phase II clinical trial.
Phase:
Phase 2
Details
Lead Sponsor:
Zhejiang Cancer Hospital
Collaborators:
First Affiliated Hospital, Sun Yat-Sen University
First People's Hospital of Foshan
The Affiliated Hospital of Guangdong Medical College
Treatments:
Carboplatin
Cisplatin
Etoposide
Etoposide phosphate